Historical record - last NADAC publication: 1/5/2018
Product Information
INVANZ 1 GM VIAL is a brand product labeled by Merck Sharp & Dohme LLC, priced at $122.4195 per EA under NDC 00006384371. Its NADAC has been published 269 times since Nov 28, 2013.
The High Outlier badge above means this manufacturer's average price in the ertapenem sodium market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
1 g/1
Manufacturer
Merck Sharp & Dohme LLCNDC
00006384371
Classification
Brand
Dosage Form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route
INTRAMUSCULAR; INTRAVENOUS
Last Updated
1/5/2018
Active Ingredients
ERTAPENEM SODIUMApproval Type
New Drug (NDA)
FDA Application
NDA021337On Market Since
11/21/2001
Pharmacological Classes
Price Statistics
The NADAC for INVANZ 1 GM VIAL has been published 269 times since Nov 28, 2013, and over the history we have for it it has risen 85.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $122.4195 per EA |
|---|---|
| All-time high | $122.4195 (Jan 16, 2019) |
| All-time low | $65.9979 (Nov 28, 2013) |
| Median price | $89.3621 |
| Average price | $93.4798 |
| Largest weekly change | +9.9% (Jan 17, 2018) |
| Weeks tracked | 269 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 2 manufacturers (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 75% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of INVANZ 1 GM VIAL?
The current National Average Drug Acquisition Cost (NADAC) for INVANZ 1 GM VIAL, manufactured by Merck Sharp & Dohme LLC, is $122.4195 per EA (NDC 00006384371), effective Jan 16, 2019.
How has the price of INVANZ 1 GM VIAL changed over time?
Over the history we have for it, the NADAC for INVANZ 1 GM VIAL has risen 85.5%. It has been tracked across 269 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for INVANZ 1 GM VIAL?
Since Nov 28, 2013, the NADAC for INVANZ 1 GM VIAL has ranged from a low of $65.9979 (Nov 28, 2013) to a high of $122.4195 (Jan 16, 2019), with a median of $89.3621 per EA.
Are there cheaper alternatives to INVANZ 1 GM VIAL?
Yes. 2 NADAC-published products share the same active ingredient, strength, and dosage form. The lowest-priced option, ERTAPENEM 1 GRAM VIAL, is $30.1598 per EA — about 75% below INVANZ 1 GM VIAL.
Who manufactures INVANZ 1 GM VIAL?
INVANZ 1 GM VIAL (NDC 00006384371) is labeled by Merck Sharp & Dohme LLC, and CMS classifies it as a brand product.
Related Drugs
Same classification